Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
IL-12 secretion induction by CD40L RNA-modified dendritic cells (CD40L RNA-modified DC-induced IL-12)
- Target
- CD40L RNA-modified DC-induced IL-12
- Molecular classification
- Cellular therapy, Gene therapy (RNA-based), Cytokine induction
01
Overview
IL-12 secretion induction by CD40L RNA-modified dendritic cells involves genetically modifying DCs to express CD40L, which activates CD40 receptors on the same or neighboring DCs, leading to robust IL-12 production. This approach aims to enhance Th1 immune responses for cancer immunotherapy and infectious disease vaccines. Optimization strategies include using truncated CD40L mRNA and post-transcriptional capping to improve IL-12 secretion. Careful regulation and safety mechanisms are crucial to prevent adverse effects such as cytokine storms and autoimmunity.
- Other names
- CD40L-modified DC-induced IL-12 secretionCD40L mRNA-transfected DC-induced IL-12 production
02
Mechanism of action
Dendritic cells are transfected with CD40L mRNA, leading to CD40L expression and autocrine/paracrine activation of CD40 receptors, resulting in IL-12 secretion and subsequent Th1 immune response.
03
Biological functions
Immune stimulationT cell activationTh1 polarizationInterleukin-12 productionAntigen presentation
04
Disease associations
Cancer immunotherapyInfectious disease vaccine adjuvantAutoimmune disease (potential risk if uncontrolled)
05
Safety considerations
Cytokine stormOff-target activation of immune cellsAutoimmunityUncontrolled Th1 polarizationTumor-induced immune suppression
06
Biomarkers
IL-12p70 secretion levelsIFN-gamma production by T cellsTh1 cell populationCD40L expression on DCs
Beyond the preview
Go deeper on IL-12 secretion induction by CD40L RNA-modified dendritic cells (CD40L RNA-modified DC-induced IL-12).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-12 secretion induction by CD40L RNA-modified dendritic cells (CD40L RNA-modified DC-induced IL-12).